172 related articles for article (PubMed ID: 16771723)
1. Prostate-specific antigen changes as a result of chlormadinone acetate administration to patients with benign prostatic hyperplasia: a retrospective multi-institutional study.
Fujimoto K; Hirao Y; Masumori N; Arai Y; Yamanaka H; Kato T; Miyazawa K
Int J Urol; 2006 May; 13(5):543-9. PubMed ID: 16771723
[TBL] [Abstract][Full Text] [Related]
2. [Rebound of prostate specific antigen after discontinuation of antiandrogen therapy for benign prostatic hyperplasia].
Noguchi K; Uemura H; Takeda M; Sekiguchi Y; Ogawa K; Hosaka M
Hinyokika Kiyo; 2000 Sep; 46(9):605-7. PubMed ID: 11107528
[TBL] [Abstract][Full Text] [Related]
3. [Changes in serum prostate specific antigen and testosterone levels after chlormadinone acetate treatment in patients with benign prostatic hyperplasia : a prospective multicenter clinical study].
Fujimoto K; Hirao Y; Ohashi Y; Shibata Y; Fuji K; Tsuji H; Shimizu N; Miyazawa K; Nagata M; Ohtani N; Furuya R; Boku E
Hinyokika Kiyo; 2011 Apr; 57(4):177-83. PubMed ID: 21646847
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the effects of chlormadinone acetate-pellet implantation and orchidectomy on benign prostatic hypertrophy in the dog.
Kawakami E; Tsutsui T; Shimizu M; Orima H; Fujita M; Ogasa A
Int J Androl; 1995 Oct; 18(5):248-55. PubMed ID: 8567095
[TBL] [Abstract][Full Text] [Related]
5. A randomized phase II trial of flutamide vs chlormadinone acetate in previously untreated advanced prostatic cancer. The Japan Flutamide Study Group.
Akaza H; Usami M; Kotake T; Koiso K; Aso Y
Jpn J Clin Oncol; 1993 Jun; 23(3):178-85. PubMed ID: 7688829
[TBL] [Abstract][Full Text] [Related]
6. [Clinical usefulness of chlormadinone acetate as an alternative antiandrogen therapy for prostate cancer relapse after combined androgen blockade therapy].
Ehara H; Katoh S; Nakane K; Katoh T; Takada T; Kojima K; Kamei S; Hagiwara N; Yuhara K; Takahashi Y; Fujimoto Y; Fujihiro S; Kanimoto Y; Deguchi T
Hinyokika Kiyo; 2009 Apr; 55(4):199-203. PubMed ID: 19462824
[TBL] [Abstract][Full Text] [Related]
7. Prognostic role of prostate-specific antigen and prostate volume for the risk of invasive therapy in patients with benign prostatic hyperplasia initially managed with alpha1-blockers and watchful waiting.
Mochtar CA; Kiemeney LA; Laguna MP; van Riemsdijk MM; Barnett GS; Debruyne FM; de la Rosette JJ
Urology; 2005 Feb; 65(2):300-5. PubMed ID: 15708042
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of disease flare with diethylstilbestrol diphosphate and chlormadinone acetate administration for two weeks prior to slow-releasing leuprolide acetate in prostatic cancer patients.
Ohuchi H; Noguchi K; Kinoshita Y; Hosaka M; Kawasaki C; Miura T; Kondo I; Harada M
Hinyokika Kiyo; 2000 Aug; 46(8):531-6. PubMed ID: 11019371
[TBL] [Abstract][Full Text] [Related]
9. Relationship between serum prostate-specific antigen and prostate volume in Korean men with benign prostatic hyperplasia: a multicentre study.
Chung BH; Hong SJ; Cho JS; Seong DH
BJU Int; 2006 Apr; 97(4):742-6. PubMed ID: 16536765
[TBL] [Abstract][Full Text] [Related]
10. Postoperative PSA and PSA velocity identify presence of prostate cancer after various surgical interventions for benign prostatic hyperplasia.
Helfand BT; Anderson CB; Fought A; Kim DY; Vyas A; McVary KT
Urology; 2009 Jul; 74(1):177-83. PubMed ID: 19428074
[TBL] [Abstract][Full Text] [Related]
11. Relationship between prostatic atrophy and apoptosis in the canine spontaneous benign prostatic hyperplasia (BPH) following chlormadinone acetate (CMA).
Murakoshi M; Ikeda R; Fukui N; Nakayama T
Tokai J Exp Clin Med; 2001 Jul; 26(2):71-5. PubMed ID: 11806444
[TBL] [Abstract][Full Text] [Related]
12. Bladder catheterization and a plasma prostate-specific antigen in patients with benign prostatic hyperplasia and complete urine retention.
Dutkiewicz S; Stepień K; Witeska A
Mater Med Pol; 1995; 27(2):71-3. PubMed ID: 8935194
[TBL] [Abstract][Full Text] [Related]
13. Recovery of serum prostate specific antigen value after interruption of antiandrogen therapy with allylestrenol for benign prostatic hyperplasia.
Noguchi K; Suzuki K; Teranishi J; Kondo K; Kishida T; Saito K; Uemura H; Kubota Y
Hinyokika Kiyo; 2006 Jul; 52(7):527-30. PubMed ID: 16910584
[TBL] [Abstract][Full Text] [Related]
14. Effect of antiandrogen, chlormadinone acetate (CMA), in canine spontaneous benign prostatic hyperplasia (BPH).
Murakoshi M; Ikada R; Tagawa M; Nakayama T
Tokai J Exp Clin Med; 2000 Apr; 25(1):11-4. PubMed ID: 11023050
[TBL] [Abstract][Full Text] [Related]
15. Validity of prostate-specific antigen as a tumour marker in men with prostate cancer managed by watchful-waiting: correlation with findings at serial endorectal magnetic resonance imaging and spectroscopic imaging.
Coakley FV; Chen I; Qayyum A; Westphalen AC; Carroll PR; Hricak H; Chen MH; Kurhanewicz J
BJU Int; 2007 Jan; 99(1):41-5. PubMed ID: 17227490
[TBL] [Abstract][Full Text] [Related]
16. Prostatic-specific antigen velocity after holmium laser enucleation of the prostate: possible predictor for the assessment of treatment effect durability for benign prostatic hyperplasia and detection of malignancy.
Elmansy HM; Elzayat EA; Sampalis JS; Elhilali MM
Urology; 2009 Nov; 74(5):1105-10. PubMed ID: 19773035
[TBL] [Abstract][Full Text] [Related]
17. The influence of baseline parameters on changes in international prostate symptom score with dutasteride, tamsulosin, and combination therapy among men with symptomatic benign prostatic hyperplasia and an enlarged prostate: 2-year data from the CombAT study.
Roehrborn CG; Siami P; Barkin J; Damião R; Becher E; Miñana B; Mirone V; Castro R; Wilson T; Montorsi F;
Eur Urol; 2009 Feb; 55(2):461-71. PubMed ID: 19013011
[TBL] [Abstract][Full Text] [Related]
18. Clinical relevance of transurethral resection of the prostate in "asymptomatic" patients with an elevated prostate-specific antigen level.
van Renterghem K; Van Koeveringe G; Achten R; Van Kerrebroeck P
Eur Urol; 2007 Sep; 52(3):819-26. PubMed ID: 17418482
[TBL] [Abstract][Full Text] [Related]
19. [Clinical studies on morphological changes in the prostate in patients with benign prostatic hypertrophy after antiandrogen therapy--by means of transrectal ultrasonotomography].
Suzuki K; Ichinose Y; Hashimoto K; Matsumoto K; Suzuki T; Imai K; Yamanaka H
Hinyokika Kiyo; 1990 May; 36(5):557-60. PubMed ID: 1698012
[TBL] [Abstract][Full Text] [Related]
20. Early diagnosis of prostate cancer in finasteride treated BPH patients.
Tarle M; Kraus O; Trnski D; Reljic A; Ruzic B; Katusic J; Spajic B; Kusic Z
Anticancer Res; 2003; 23(1B):693-6. PubMed ID: 12680169
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]